Company: ABBV
Filing Date: 2025-03-24
Form Type: DEF 14A
Source: 0001558370-25-003537
Chunk: 64

Company: AbbVie Inc.
Filing Date: 2025-03-24
Form: DEF 14A
Chunk 64
---
,448 |
| A. Saleki-Gerhardt | ​ | Deferred Compensation Plan | ​ |             0 | ​ |             0 | ​ |     86,043 | ​ |             0 | ​ |    680,218 |
| T. Richmond        | ​ | Deferred Compensation Plan | ​ |             0 | ​ |             0 | ​ |     18,014 | ​ |             0 | ​ |    128,007 |

| (1) | Mr. Stewart, Dr. Saleki-Gerhardt and Mr. Richmond ceased contributions to the Deferred Compensation Plan in 2009, 2008 and 2010, respectively. |

| (2) | The plan permits participants to defer up to 75% of their base salary and up to 75% of their annual cash incentives and credits a participant’s account with an amount equal to the employer matching contributions that otherwise would have been made for the participant under AbbVie’s tax-qualified defined contribution plan. Participants may direct the investment of their deferral accounts into one or more of several funds chosen by the administrator, and the deferral account is credited with investment returns based on the performance of the fund(s) selected. During 2024, the weighted average rate of return credited to the account was 4.7% for Mr. Stewart, 14.5% for Dr. Saleki-Gerhardt and 16.4% for Mr. Richmond. |

The plan provides for cash distributions in either a lump sum or installments after separation from service and permits in-service withdrawals in accordance with specific procedures. Participants make distribution elections each year that apply to the deferrals to be made in the following calendar year, in accordance with the requirements of Internal Revenue Code Section 409A. Participants may request withdrawals due to financial hardship; if a hardship withdrawal is approved, it is limited to the amount needed to address the hardship.

| (3) | The amounts reported in this column are not included in the Summary Compensation Table of this proxy statement. |

| (4) | The amounts reported in this column have not been previously reported as compensation in AbbVie’s Summary Compensation Tables because they relate to contributions made before the applicable individual became an NEO. |

2025 Proxy Statement |63

| ​                      | ​ |
| EXECUTIVE COMPENSATION | ​ |

REQUIRED PAY RATIO DISCLOSURE As required by Section 953(b) of the Dodd-Frank Wall Street Reform and Consumer Protection Act and